Loading...
Use of anti-TNF drug levels to optimise patient management
Anti-tumour necrosis factor (TNF) therapies, such as infliximab, adalimumab, certolizumab pegol and golimumab, have been proven to be effective for the treatment of patients with Crohn's disease and ulcerative colitis. However, 10%–30% of patients with inflammatory bowel disease (IBD) show no i...
Na minha lista:
| Udgivet i: | Frontline Gastroenterol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5369499/ https://ncbi.nlm.nih.gov/pubmed/28839870 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/flgastro-2016-100685 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|